Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CSL ( (AU:CSL) ) has shared an announcement.
CSL Limited has notified the ASX of the issue of 39,627 new ordinary fully paid shares following the conversion of previously unquoted securities. The shares were issued on 2 March 2026 and disclosed via an Appendix 3G filing, reflecting the exercise or conversion of unquoted options or other convertible instruments into listed equity.
The move marginally increases CSL’s share capital and may reflect ongoing employee or executive incentive schemes, or other capital management programs using unquoted equity. While modest in scale, such conversions can incrementally dilute existing shareholders and signal continued utilisation of equity-based remuneration or financing structures by the biopharmaceutical group.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$164.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited is a global biopharmaceutical company listed on the ASX, best known for developing and manufacturing vaccines, plasma-derived therapies and other specialty biotherapeutics. The company focuses on treatments for serious and rare diseases, blood disorders and immunological conditions, and serves healthcare systems and patients in key markets worldwide.
Average Trading Volume: 1,132,511
Technical Sentiment Signal: Sell
Current Market Cap: A$71.46B
For detailed information about CSL stock, go to TipRanks’ Stock Analysis page.